Dyne Q2 net loss $110.9M extends cash runway into Q3 2027 on $215M offering

Dyne Therapeutics, Inc.

2025-Q2 EPS reported -$2.02

Net loss $110.9M ($0.97/sh) vs $65.1M ($0.70) in Q2 2024; R&D expenses $99.2M.
Cash $683.9M; July offering net $215.2M; Hercules $100M initial loan; runway into Q3 2027.
DYNE-251 DMD registrational cohort enrolled (32 pts); data late 2025; potential BLA early 2026.
DYNE-101 DM1 FDA Breakthrough Therapy; 60-pt cohort enrollment Q4 2025; data mid-2026; BLA late 2026.
Hercules $275M senior secured loan; 5 tranches; milestones-based drawdown; final tranche subject to approval.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.